Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment
Go back to Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment(AMEX: CLABD) | Delayed: 4.35 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $4.35 | 52 Week High | $ | |||
Open | $2.77 | 52 Week Low | $ | |||
Day High | $4.35 | P/E | N/A | |||
Day Low | $4.35 | EPS | $ | |||
Volume | 23,412 |
Majesco Entertainment Company (NASDAQ: COOL) | Delayed: 11.00 +0.01 (0.09%) | |||||
---|---|---|---|---|---|---|
Previous Close | $10.99 | 52 Week High | $4.10 | |||
Open | $10.99 | 52 Week Low | $0.61 | |||
Day High | $11.00 | P/E | N/A | |||
Day Low | $10.99 | EPS | $-0.30 | |||
Volume | 1,039 |